Novel therapeutic strategies for Alzheimer's disease based on the forgotten reproductive hormones.
The relationship between hormones and Alzheimer's disease (AD) has been intensely researched. While the majority of this work has focused on the sex steroids, estrogens, and more recently androgens, a serendipitous patient encounter led one of us (R.L.B.) to question whether other hormones of the hypothalamic-pituitary-gonadal axis might play a role in the pathogenesis of AD. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum gonadotropin concentrations. Indeed, there is growing evidence that the gonadotropin luteinizing hormone, which regulates serum estrogen and testosterone concentrations, is an important causative factor in the development of AD. This review provides information supporting the 'gonadotropin hypothesis'. We put forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of AD and discusses potential therapeutic anti-gonadotropin compounds.
Gregory
C W
CW
Voyager Pharmaceutical Corporation, Raleigh, North Carolina 27516, USA.
Bowen
R L
RL
D000375:Aging; D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology; D006062:Gonadotropins / Q000502:physiology*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors
D004791:Enzyme Inhibitors; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D016202:N-Methylaspartate; D007986:Luteinizing Hormone
Eur J Heart Fail. 2012 Aug;14 (8):931-8
22613584
EuroIntervention. 2016 Feb;11(10 ):1126-31
26342591
Eur J Heart Fail. 2014 Nov;16(11):1223-9
25314900
J Am Coll Cardiol. 2013 Dec 24;62(25):2370-7
24013059
Am J Cardiol. 2001 Feb 1;87(3):298-304
11165964
BMC Cardiovasc Disord. 2015 May 14;15:43
25971307
Europace. 2011 Jun;13(6):829-38
21486916
Circulation. 2014 Jun 10;129(23):e521-643
24589853
J Am Coll Cardiol. 2005 Dec 6;46(11):2134-40
16325053
Am J Cardiol. 2015 Feb 15;115(4):487-92
25529545
EuroIntervention. 2016 Jul 20;12 (4):508-14
26348678
J Am Coll Cardiol. 2013 Jul 23;62(4):317-28
23665364
N Engl J Med. 1996 Nov 7;335(19):1417-23
8875918
JACC Cardiovasc Interv. 2014 Nov;7(11):1326-8
25326746
JACC Cardiovasc Interv. 2015 Nov;8(13):1735-44
26476608
Catheter Cardiovasc Interv. 2014 Jul 1;84(1):137-46
24323541
Arch Cardiovasc Dis. 2015 Feb;108(2):88-96
25662004
J Am Coll Cardiol. 2011 Nov 15;58(21):2183-9
22078424
J Heart Valve Dis. 2013 Sep;22(5):651-9
24383376
J Med Econ. 2014 Aug;17(8):599-615
24826880
Circulation. 2011 Aug 23;124(8):912-9
21810666
Eur Heart J. 2007 Jun;28(11):1358-65
17350971
JACC Cardiovasc Interv. 2014 Jul;7(7):e85-6
24954567
N Engl J Med. 2011 Apr 14;364(15):1395-406
21463154
J Am Coll Cardiol. 2014 Jul 15;64(2):172-81
25011722
Ann Biomed Eng. 2013 May;41(5):1049-61
23389556
Circulation. 2002 Sep 10;106(11):1355-61
12221052
Circulation. 2009 Jul 28;120(4):326-33
19597051
Eur J Cardiothorac Surg. 1998 Mar;13(3):240-5; discussion 245-6
9628372
J Interv Cardiol. 2015 Apr;28(2):164-71
25858050
Eur Heart J. 2012 Oct;33(19):2451-96
22922415
Int J Cardiol. 2015 Nov 1;198:75-80
26156318
J Med Econ. 2013 Nov;16(11):1317-26
24040937
Circulation. 2010 Apr 27;121(16):1848-57
20385927
Eur Heart J. 2015 Jul 7;36(26):1651-9
25870204
Clin Res Cardiol. 2015 Dec;104(12):1044-53
26022739
Lancet. 2006 Sep 16;368(9540):1005-11
16980116
J Am Coll Cardiol. 2013 Sep 17;62(12):1052-61
23747789